FLGT News and Press, Fulgent Genetics Inc. From 10/13/21

Most investors will tell you they love to buy stocks when they are cheap. But that typically means taking on some uncertainty. After all, Wall Street doesn't sell a stock unless it believes there is a better place for the money -- at least in the short term. That's why long-term investi...

Fulgent's recent quarters have featured staggering revenue growth, but there's more under the surface. The core genetic testing business is the driver of future growth. Current valuation provides a good entry point for investors who can stomach the volatility. For further de...

Fulgent Genetics ' (NASDAQ: FLGT) sales soared thanks to its COVID-19 tests. Its stock more than quadrupled in 2020 and is up over 50% so far this year. In this Motley Fool Live video recorded on Sept. 29, 2021 , Motley Fool contributors Keith Speights and Brian Orelli discu...

Thermo Fisher forms part of the Life Sciences and Tools Industry. With more vaccination, COVID diagnostic sales have fallen in the second quarter compared to the prior one, but thanks to higher base revenues, the company has actually managed to exhibit growth. I go deeper into fin...

With U.S. COVID-19 cases expected to fall over 90% in the next six months, some investors may have concerns about genetic testing company Fulgent Genetics (NASDAQ: FLGT) -- one of the primary COVID-19 testing companies during the pandemic -- thinking that its success is over. This, ...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Signs that the stock market is expensive are all around us. For one, Warren Buffett's favorite indicator -- the ratio of total market capitalization of the stock market to gross domestic product -- is at an all-time high. At 239%, it's higher than it was the before the dot-com crash of 2001...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it will be partnering ...

One of the biggest hurdles people face when they think about buying stocks is feeling like they don't have enough money to make a difference. But over time, even a little bit of money can grow into an impressive portfolio. In the last 40 years, the S&P 500 index has gained 3,600%. ...

There were a lot of companies that jumped to action last year in the fight against the SARS-CoV-2 virus. Videoconferencing, e-commerce, delivery apps, drug development and diagnostics all prospered. In that latter category, one company proved it has a business model to succeed long afte...